Related Experiment Video
Updated: Jan 20, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation
Chaoyun Pan1, Jaemoo Chun1, Dan Li1
1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract:
Microtubule-associated serine/threonine kinase 1 (MAST1) is a central driver of cisplatin resistance in human cancers. However, the molecular mechanism regulating MAST1 levels in cisplatin-resistant tumors is unknown. Through a proteomics screen, we identified the heat shock protein 90 B (hsp90B) chaperone as a direct MAST1 binding partner essential for its stabilization. Targeting hsp90B sensitized cancer cells to cisplatin predominantly through MAST1 destabilization. Mechanistically, interaction of hsp90B with MAST1 blocked ubiquitination of MAST1 at lysines 317 and 545 by the E3 ubiquitin ligase CHIP and prevented proteasomal degradation. The hsp90B-MAST1-CHIP signaling axis and its relationship with cisplatin response were clinically validated in cancer patients. Furthermore, combined treatment with a hsp90 inhibitor and the MAST1 inhibitor lestaurtinib further abrogated MAST1 activity and consequently enhanced cisplatin-induced tumor growth arrest in a patient-derived xenograft model. Our study not only uncovers the regulatory mechanism of MAST1 in tumors but also suggests a promising combinatorial therapy to overcome cisplatin resistance in human cancers.
Insights
Heat shock protein 90 B (hsp90B) stabilizes MAST1, driving cisplatin resistance in cancers. Targeting hsp90B destabilizes MAST1, sensitizing tumors to cisplatin and offering a novel therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Microtubule-associated serine/threonine kinase 1 (MAST1) drives cisplatin resistance in human cancers.
- The precise molecular mechanisms governing MAST1 levels in resistant tumors remain unclear.
Purpose of the Study:
- To elucidate the regulatory mechanism of MAST1 in cisplatin-resistant cancers.
- To identify novel therapeutic targets for overcoming cisplatin resistance.
Main Methods:
- Proteomics screening to identify MAST1 binding partners.
- In vitro assays to assess protein stabilization and ubiquitination.
- In vivo studies using patient-derived xenograft models.
Main Results:
- Heat shock protein 90 B (hsp90B) was identified as a MAST1 binding partner crucial for its stabilization.
- Targeting hsp90B led to MAST1 destabilization and sensitized cancer cells to cisplatin.
- hsp90B interaction inhibited CHIP-mediated ubiquitination and proteasomal degradation of MAST1.
- The hsp90B-MAST1-CHIP axis was clinically validated in cancer patients.
- Combined hsp90 and MAST1 inhibition enhanced cisplatin efficacy in a xenograft model.
Conclusions:
- The hsp90B-MAST1-CHIP signaling axis is a key regulator of MAST1 stability and cisplatin response.
- Inhibiting hsp90B or combining hsp90 and MAST1 inhibitors presents a promising strategy to overcome cisplatin resistance.
More Related Videos
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation
Proteins: From Genes to Degradation
Transcription is the synthesis of RNA...
Self-Evaluation: Self-Enhancement and Self-Verification
Zones of Protection
Protective zones are defined by closed dashed lines, containing one or more components. A key characteristic of these zones is the strategic placement of...
Protection of Alcohols
Protection
It defines a protecting group as the masking agent to make the more reactive species inert to a given set of conditions. This concept is depicted via the illustration of liquid flow through different outlets in an assembly of pipes. The analogy helps to understand the role...

